452 related articles for article (PubMed ID: 33484775)
1. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM; Bowlus CL; Mayo MJ; Kremer AE; Vierling JM; Kowdley KV; Levy C; Villamil A; Ladrón de Guevara Cetina AL; Janczewska E; Zigmond E; Jeong SH; Yilmaz Y; Kallis Y; Corpechot C; Buggisch P; Invernizzi P; Londoño Hurtado MC; Bergheanu S; Yang K; Choi YJ; Crittenden DB; McWherter CA;
N Engl J Med; 2024 Feb; 390(9):783-794. PubMed ID: 38381664
[TBL] [Abstract][Full Text] [Related]
5. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Jones D; Boudes PF; Swain MG; Bowlus CL; Galambos MR; Bacon BR; Doerffel Y; Gitlin N; Gordon SC; Odin JA; Sheridan D; Wörns MA; Clark V; Corless L; Hartmann H; Jonas ME; Kremer AE; Mells GF; Buggisch P; Freilich BL; Levy C; Vierling JM; Bernstein DE; Hartleb M; Janczewska E; Rochling F; Shah H; Shiffman ML; Smith JH; Choi YJ; Steinberg A; Varga M; Chera H; Martin R; McWherter CA; Hirschfield GM
Lancet Gastroenterol Hepatol; 2017 Oct; 2(10):716-726. PubMed ID: 28818518
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
[TBL] [Abstract][Full Text] [Related]
7. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Bowlus CL; Galambos MR; Aspinall RJ; Hirschfield GM; Jones DEJ; Dörffel Y; Gordon SC; Harrison SA; Kremer AE; Mayo MJ; Thuluvath PJ; Levy C; Swain MG; Neff GW; Sheridan DA; Stanca CM; Berg CP; Goel A; Shiffman ML; Vierling JM; Boudes P; Steinberg A; Choi YJ; McWherter CA
J Hepatol; 2022 Aug; 77(2):353-364. PubMed ID: 35367282
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
9. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
10. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM; Shiffman ML; Gulamhusein A; Kowdley KV; Vierling JM; Levy C; Kremer AE; Zigmond E; Andreone P; Gordon SC; Bowlus CL; Lawitz EJ; Aspinall RJ; Pratt DS; Raikhelson K; Gonzalez-Huezo MS; Heneghan MA; Jeong SH; Ladrón de Guevara AL; Mayo MJ; Dalekos GN; Drenth JPH; Janczewska E; Leggett BA; Nevens F; Vargas V; Zuckerman E; Corpechot C; Fassio E; Hinrichsen H; Invernizzi P; Trivedi PJ; Forman L; Jones DEJ; Ryder SD; Swain MG; Steinberg A; Boudes PF; Choi YJ; McWherter CA;
Hepatology; 2023 Aug; 78(2):397-415. PubMed ID: 37386786
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
12. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.
Lin W; Wang JX; Liu YJ
Syst Rev; 2024 Jan; 13(1):46. PubMed ID: 38287391
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
Poupon RE; Eschwège E; Poupon R
J Hepatol; 1990 Jul; 11(1):16-21. PubMed ID: 1975819
[TBL] [Abstract][Full Text] [Related]
14. Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.
Invernizzi P; Carbone M; Jones D; Levy C; Little N; Wiesel P; Nevens F;
Liver Int; 2023 Jul; 43(7):1507-1522. PubMed ID: 37183520
[TBL] [Abstract][Full Text] [Related]
15. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.
Cortez-Pinto H; Liberal R; Lopes S; Machado MV; Carvalho J; Dias T; Santos A; Agostinho C; Figueiredo P; Loureiro R; Martins A; Alexandrino G; Cotrim I; Leal C; Presa J; Mesquita M; Nunes J; Gouveia C; Vale AHE; Alves AL; Coelho M; Maia L; Pedroto I; Banhudo A; Pinto JS; Gomes MV; Oliveira J; Andreozzi V; Calinas F
United European Gastroenterol J; 2021 Jul; 9(6):699-706. PubMed ID: 34102008
[TBL] [Abstract][Full Text] [Related]
16. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
17. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC.
Battezzati PM; Podda M; Bianchi FB; Naccarato R; Orlandi F; Surrenti C; Pagliaro L; Manenti F
J Hepatol; 1993 Mar; 17(3):332-8. PubMed ID: 8315262
[TBL] [Abstract][Full Text] [Related]
19. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
[TBL] [Abstract][Full Text] [Related]
20. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]